MacroGenics Cultura de la Empresa

Mr. Eric Blasius Risser has been Chief Business Officer and Senior Vice President of Business Development and Portfolio Management at MacroGenics, Inc. since September 2016. Mr. Risser served as Vice President of Business Development at MacroGenics, Inc. since March 2009. He has a wealth of strategic and transactional experience. Prior to joining MacroGenics, he served as Senior Director, Business Development at Johnson & Johnson Pharmaceuticals, which he joined in 2003. While at Johnson & Johnson, he was responsible for leading global transactions in the pharmaceuticals area, including company acquisitions, product licenses and research collaborations. His areas of expertise include originating collaboration opportunities, managing multi-disciplinary project teams, structuring and negotiating transactions and formulating integration and alliance management plans. Before Johnson & Johnson, he started and built a successful consulting practice that provided counsel to emerging life science companies in the United States and Europe. He has also worked as a venture capitalist with BankAmerica Ventures as an investment banker with Lehman Brothers, where he began his career in their New York and London offices. Mr. Risser holds an M.B.A. from Stanford University and a B.A. from Yale University.

Dr. Ezio Bonvini, M.D., has been Chief Scientific Officer and Senior Vice President of Research at MacroGenics, Inc. since September 2016. Dr. Bonvini served as Vice President of Clinical Research at MacroGenics, Inc. Dr. Bonvini, a hematologist by training, is an expert in immunobiology and joined MacroGenics since June 2003 and served as Vice President of Research since November 2004. He joined MacroGenics, Inc. in June 2003. He has MacroGenics with 24 years of research, regulatory and clinical trial design experience spent at the National Cancer Institute, the National Institutes of Health and more recently at the Food and Drug Administration (FDA) in the Center for Biologics Evaluation and Research (CBER), which is responsible for regulating therapeutic monoclonal antibodies and other proteins. Dr. Bonvinis research dealt with the molecular mechanism of signal transduction by immune receptors in leukocyte activation. During his tenure at CBER, he held several leadership positions in the Division of Monoclonal Antibodies, most recently as the Acting Deputy Division Director and Chief of the Laboratory of Immunobiology, where he was responsible for supervising the research program and the review of monoclonal antibody products from IND to BLA stages. While at the FDA, he received several awards for his scientific and regulatory work. His familiarity with all aspects of scientific, regulatory and clinical development process for biologics will help focus MacroGenics R&D development of FDA-compliant product candidates from the earliest stages of preclinical development. Dr. Bonvini received a Diploma in Science from the Scientific Lyceum in Genoa, Italy and his M.D. and Specialty Certification in Clinical Hematology from the University of Genoa, School of Medicine.

Mr. James Karrels, also known as Jim, has been the Chief Financial Officer of MacroGenics, Inc, since May 06, 2008 and serves as its Secretary and Senior Vice President. Mr. Karrels served as Vice President of MacroGenics, Inc, since May 6, 2008. He has a wealth of financial and analytical experience. He had been at Jazz Pharmaceuticals, Inc. since 2005 and most recently served as its Executive Director of Finance. While at Jazz Pharmaceuticals, he was responsible for it's financial planning and analysis and investor relations activities. He began his career as an analyst at Merrill Lynch & Co. in 1989 and advanced to the position of Director in the Healthcare Investment Banking Group. During his tenure at Merrill Lynch, he participated in more than 30 sole or lead-managed transactions, representing over $25 billion in aggregate transaction value. His activities included the marketing, structuring and execution of IPOs, equity and convertible debt financings, mergers and acquisitions, spin-offs and other transactions. Mr. Karrels holds an MBA from Stanford University and a BBA from the University of Notre Dame.

Dr. Jon M. Wigginton, M.D., has been a Senior Vice President of Clinical Development at MacroGenics, Inc. since August 2013 and has been its Chief Medical Officer since February 2016 and served as its Senior Vice President of Clinical Research since August 2013. Dr. Wigginton served as Therapeutic Area Head of Immuno-Oncology, Early Clinical Research and Executive Director of Discovery Medicine-Clinical Oncology at Bristol-Myers Squibb (BMS), where he led the early clinical development of the BMS Immuno-Oncology portfolio including anti-PD-1 and anti-PD-L1. Prior to joining BMS, Dr. Wigginton served as the Director of Clinical Oncology at Merck Research Laboratories, where he led early- and late-stage clinical development teams for small molecules and biologics. During his academic career, he held several positions at the National Cancer Institute Center for Cancer Research (NCI-CCR), including Head of Investigational Biologics Section, Pediatric Oncology Branch. Dr. Wigginton served as President of the International Society for the Biological Therapy of Cancer (now SITC). He serves as Member of Advisory Board at UbiVac, LLC. He is the author of over 50 manuscripts and reviews and is the recipient of multiple awards for scientific accomplishment from sources including the NIH, NCI, USPHS, iSBTc, ISICR, Children's Cancer Foundation, Merck and BMS. Dr. Wigginton received his M.D. and B.S. in Biology from the University of Michigan.

Dr. Thomas M. Spitznagel, Ph.D. also known as Tom, serves as Senior Vice President of Biopharmaceutical Development and Manufacturing at MacroGenics, Inc. Dr. Spitznagel joined MacroGenics in 2013 and has overall responsibility for biopharmaceutical process development and manufacturing of MacroGenics' product candidates, including several Fc-optimized monoclonal antibodies and DART molecules, as well as oversight of the facilities and engineering functions. Prior to joining MacroGenics, Dr. Spitznagel served as Vice President of BioPharmaceutical Development at Human Genome Sciences Inc. from May 2008 to 2013, where he was responsible for oversight of Analytical Development, Formulation and Drug Delivery, Purification Sciences and Fermentation and Cell Culture Sciences. Dr. Spitznagel joined HGS in March 1998 as Group Leader of Formulation. Prior to joining HGS, Dr. Spitznagel was Senior Scientist at Nabi Biopharmaceuticals from 1996-1998 and a Staff Engineer at Genetics Institute from 1992-1996. During his tenure at Nabi, he was responsible for scale-up and development of the purification process for polysaccharide-protein conjugate vaccines. During his tenure at Genetics Institute, he was responsible for formulation and delivery system development for rhBMP-2, as well as finished product process development. Dr. Spitznagel earned his BS in Chemical Engineering at M.I.T and his Ph.D. in Chemical Engineering at the University of California, Berkeley.

Mr. Jeffrey Peters has been Acting General Counsel and Vice President of Legal Affairs at MacroGenics, Inc. since June 20, 2017. Mr. Peters joined MacroGenics, Inc. in August 2015 as Vice President, Deputy General Counsel. Mr. Peters served as Deputy General Counsel, Health, for the Biotechnology Innovation Organization (BIO), the leading national trade association for the biotechnology industry. While at BIO, Mr. Peters served as the primary legal counsel on health regulatory and related matters, including legal and policy matters affecting all aspects of biopharmaceutical product discovery, development and delivery. Prior to BIO, Mr. Peters was with MedImmune, the global biologics arm of AstraZeneca. From 2005 through 2013, Mr. Peters had positions of increasing responsibility in the MedImmune legal department, culminating as Vice President and Deputy General Counsel. Before joining MedImmune, Mr. Peters was in private practice for almost a decade, joining MedImmune from the life sciences practice group at Latham & Watkins LLP, in Washington, D.C. He is a member of the bar in the states of Massachusetts and New York and in the District of Columbia. Mr. Peters holds a J.D. from the University of Pennsylvania Law School and a B.A. in both Politics and Literature from Brandeis University.

Michael Richman serves as the COO for MacroGenics. Michael started at MacroGenics in December of . Michael is based in the Washington D.C. Metro Area.

Syd Johnson serves as the VP, Antibody Engineering for MacroGenics. Syd started at MacroGenics in September of 2001. Syd is based in the Washington D.C. Metro Area.